newsfilter
← Latest News
GlobeNewswire·

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of